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Background
Adoptive cell transfer (ACT) with autologous tumor-
reactive T cells is a promising strategy in cancer immu-
notherapy, but treatment of solid tumors is limited by the
rapid decline in function of the transplanted T cells. In
order to maintain high numbers of viable antigen-specific
cytotoxic T cells in tumors, co-administration of support-
ing immunostimulant agents together with transferred
cells is often necessary in clinical practice. However, the
high systemic doses of such agents needed to enhance
T cell functionality can also result in serious side effects.
Methods
Here, we developed a carrier-free strategy to deliver cyto-
kines specifically to adoptively transferred T cells for can-
cer immunotherapy. IL-2-Fc or an IL-15 superagonist
were chemically cross-linked with a disulfide linker to
form protein nanogels (NGs), which were conjugated to
the plasma membrane of ACT T cells.
Results
These NGs had exceptionally high loading of cytokines
(~70 wt%) and released native protein in physiological
conditions in a sustained manner through breakdown of
the degradable disulfide linker in response to the acti-
vated T cell surface reduction activity. Cytokine-NGs
were chemically conjugated onto the plasma membrane
of donor T cells, enabling continuous pseudo-autocrine
release of cytokine for stimulation of transferred CD8+
T cells. Transferred pmel-1 CD8+ T cells with opti-
mized number of NGs conjugated per cell showed
enhanced expansion and long persistence in B16F10
tumor bearing mice. Quantification of transferred
Thy1.1+CD8+ T cells in tumors at Day 13 showed that
T cells with conjugated cytokine-NGs expanded ~80
fold more than the T cells with systemically adminis-
tered free cytokine.
Conclusions
We demonstrated that the cytokine-NG-T cell conjuga-
tion strategy could augment transferred T cell expansion
efficiently and specifically in vivo, and thus improve the
therapeutic efficacy. This T cell-NG “back pack” approach
provides a readily generalizable strategy to provide auto-
crine protein drug support to donor cells to enhance the
safety and efficacy of ACT.
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